NewAmsterdam Pharma

News
heart-840x470

NewAmsterdam's CETP renaissance gathers pace

NewAmsterdam Pharma's bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib.